Dec. 27 at 6:22 PM
$CMPX per Nasdaq, institutional investors added 45m shares in q3 with only 2.9m sales. They must read the decline in events to speak to the efficacy of tovecimig in BLT. No otherwise standard of care for BLT. I added on expectation that good chance that tovecimig fills the void in a
$3B second line setting. Bigger still if goes first line. Do your DD — including considering the other promising pipeline assets.
